• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PRA Health Sciences, Inc.

    7/12/21 4:27:12 PM ET
    $PRAH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PRAH alert in real time by email
    SC 13G 1 PRAH_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    PRA HEALTH SCIENCES, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.01 PER SHARE
    (Title of Class of Securities)

    69354M108
    (CUSIP Number)

    JUNE 30, 2021
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    2
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    3
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     ICS Opportunities, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    4
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     ICS Opportunities II LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    5
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Assets, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    6
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium International Management LP
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    PN


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    7
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    8
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    9
      of   
    16

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    69354M108

     SCHEDULE 13G

    Page  
    10
      of   
    16
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      PRA Health Sciences, Inc., a Delaware corporation (the "Issuer").
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    4130 ParkLake Avenue, Suite 400
    Raleigh, North Carolina 27612

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      ICS Opportunities, Ltd.
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      ICS Opportunities II LLC
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      Integrated Assets, Ltd.
    c/o Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Cayman Islands
     
       
     
      Millennium International Management LP
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.01 per share ("Common Stock")
     
      (e) CUSIP Number:
         
        69354M108


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    11
      of   
    16

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    69354M108

     SCHEDULE 13G

    Page  
    12
      of   
    16
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned

       As of the close of business on June 30, 2021, the reporting persons beneficially owned an aggregate of 3,730,627 shares of the Issuer’s Common Stock or 5.8% of the Issuer’s Common Stock outstanding, which percentage was calculated based on 64,795,400 shares of the Issuer’s Common Stock outstanding as of April 26, 2021, as reported in the Issuer’s Form 10-Q, filed on April 29, 2021.

       On July 1, 2021, the Issuer was acquired by ICON plc. Upon completion of the acquisition, pursuant to the terms of the merger agreement, the Issuer became became a wholly owned subsidiary of ICON plc. Under the terms of the merger, each share of the Issuer’s Common Stock was cancelled and exchanged for $80 in cash and 0.4125 ordinary shares of ICON plc. Accordingly, as a result of the consummation of the merger, the reporting persons no longer beneficially owned any shares of the Issuer’s Common Stock.

    (b) Percent of Class:   

       0.0%


                         
    CUSIP No.
     
    69354M108

     SCHEDULE 13G

    Page  
    13
      of   
    16

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       -0-

    (ii) Shared power to vote or to direct the vote

       -0- (See Item 4(a))

     (iii) Sole power to dispose or to direct the disposition of

       -0-

    (iv) Shared power to dispose or to direct the disposition of

       -0- (See Item 4(a))

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    14
      of   
    16

    Exhibits:

    Exhibit I: Joint Filing Agreement, dated as of July 9, 2021, by and among Integrated Core Strategies (US) LLC, ICS Opportunities, Ltd., ICS Opportunities II LLC, Integrated Assets, Ltd., Millennium International Management LP, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    15
      of   
    16
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: July 9, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES II LLC

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    69354M108

    SCHEDULE 13G

    Page  
    16
      of   
    16
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.01 per share, of PRA Health Sciences, Inc., a Delaware corporation, will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: July 9, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES II LLC

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $PRAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

      Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e

      3/3/25 8:00:00 AM ET
      $AKYA
      $CMBM
      $CSCO
      $DOMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Radio And Television Broadcasting And Communications Equipment
      Technology
    • DT Midstream Set to Join S&P MidCap 400

      NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.   Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker

      6/28/21 6:07:00 PM ET
      $SPGI
      $DTE
      $ICLR
      $PRAH
      Finance: Consumer Services
      Finance
      Electric Utilities: Central
      Utilities
    • Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

      Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re

      6/23/21 8:01:00 AM ET
      $PRAH
      $MDRX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      EDP Services
      Technology

    $PRAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

      Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

      5/26/21 7:00:00 AM ET
      $AVXL
      $TMDX
      $PRAH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Commercial Physical & Biological Resarch

    $PRAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PRA Health Sciences, Inc.

      SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 4:27:12 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 10:21:51 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      4/12/21 2:07:51 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PRA Health Sciences downgraded by Truist with a new price target

      Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously

      5/10/21 7:22:17 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Credit Suisse reiterated coverage on PRA Health Sciences with a new price target

      Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously

      4/29/21 10:40:10 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PRA Health Sciences downgraded by Baird with a new price target

      Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00

      4/20/21 7:51:16 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    SEC Filings

    See more
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:48:41 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:45:04 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:47:14 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:29:52 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:26:22 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 5:47:14 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care